Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Forsyth

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
JAMA Psychiatry|April 8, 2026
General Anesthesia and Discrete Components of Ketamine NeurophysiologyBen Deverett, Duan Li, Theresa R Lii, et al.
Biological Psychiatry|March 30, 2023
Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled TrialRobin J Murphy, Rachael Sumner, William Evans, et al.
Neuropharmacology|November 7, 2025
LSD microdosing in major depressive disorder: results from an open-label trialDimitri Daldegan-Bueno, Carina Joy Donegan, Rachael Sumner, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|February 19, 2026
LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a phase 2a trialDimitri Daldegan-Bueno, Carina Joy Donegan, Rachael Sumner, et al.
Human Brain Mapping|October 22, 2019
Effects of ketamine and midazolam on resting state connectivity and comparison with ENIGMA connectivity deficit patterns in schizophreniaBhim M Adhikari, Juergen Dukart, Joerg F Hipp, et al.
Pilot and Feasibility Studies|October 5, 2023
An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1)Carina Joy Donegan, Dimitri Daldegan-Bueno, Rachael Sumner, et al.
Human Microbiome Journal|September 6, 2021
Adjunctive dental therapies in caries-active children: Shifting the cariogenic salivary microbiome from dysbiosis towards non-cariogenic healthClaudia Lyashenko, Elisa Herrman, Jessica Irwin, et al.
Translational Psychiatry|February 16, 2023
Functional connectivity signatures of NMDAR dysfunction in schizophrenia-integrating findings from imaging genetics and pharmaco-fMRIArnim J Gaebler, Nilüfer Fakour, Felix Stöhr, et al.
Trials|August 24, 2024
LSDDEP2: study protocol for a randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorderDimitri Daldegan-Bueno, Carina Joy Donegan, Anna Forsyth, et al.
Biorxiv : the Preprint Server for Biology|May 7, 2026
Linking human brain functional connectivity to underlying neurotransmissionLeon D Lotter, Golia Shafiei, Daouia Larabi, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
JAMA Psychiatry|April 8, 2026
General Anesthesia and Discrete Components of Ketamine NeurophysiologyBen Deverett, Duan Li, Theresa R Lii, et al.
Biological Psychiatry|March 30, 2023
Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled TrialRobin J Murphy, Rachael Sumner, William Evans, et al.
Neuropharmacology|November 7, 2025
LSD microdosing in major depressive disorder: results from an open-label trialDimitri Daldegan-Bueno, Carina Joy Donegan, Rachael Sumner, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|February 19, 2026
LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a phase 2a trialDimitri Daldegan-Bueno, Carina Joy Donegan, Rachael Sumner, et al.
Human Brain Mapping|October 22, 2019
Effects of ketamine and midazolam on resting state connectivity and comparison with ENIGMA connectivity deficit patterns in schizophreniaBhim M Adhikari, Juergen Dukart, Joerg F Hipp, et al.
Pilot and Feasibility Studies|October 5, 2023
An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1)Carina Joy Donegan, Dimitri Daldegan-Bueno, Rachael Sumner, et al.
Human Microbiome Journal|September 6, 2021
Adjunctive dental therapies in caries-active children: Shifting the cariogenic salivary microbiome from dysbiosis towards non-cariogenic healthClaudia Lyashenko, Elisa Herrman, Jessica Irwin, et al.
Translational Psychiatry|February 16, 2023
Functional connectivity signatures of NMDAR dysfunction in schizophrenia-integrating findings from imaging genetics and pharmaco-fMRIArnim J Gaebler, Nilüfer Fakour, Felix Stöhr, et al.
Trials|August 24, 2024
LSDDEP2: study protocol for a randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorderDimitri Daldegan-Bueno, Carina Joy Donegan, Anna Forsyth, et al.
Biorxiv : the Preprint Server for Biology|May 7, 2026
Linking human brain functional connectivity to underlying neurotransmissionLeon D Lotter, Golia Shafiei, Daouia Larabi, et al.
Pageof 4